Holen Sie sich die Stockscreener-App
15.29
0.16%
0.025
Schlusskurs vom Vortag:
$15.26
Offen:
$15.26
24-Stunden-Volumen:
32,851
Relative Volume:
0.35
Marktkapitalisierung:
$13.32B
Einnahmen:
$630.20M
Nettoeinkommen (Verlust:
$37.73M
KGV:
76.42
EPS:
0.2
Netto-Cashflow:
$-17.44M
1W Leistung:
+10.04%
1M Leistung:
+2.93%
6M Leistung:
-10.40%
1J Leistung:
-17.11%
1-Tages-Spanne:
$15.02
$15.39
1-Wochen-Bereich:
$13.39
$15.39
52-Wochen-Spanne:
$11.51
$21.50
Hutchmed China Limited Adr Stock (HCM) Company Profile
Vergleichen Sie HCM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HCM
Hutchmed China Limited Adr
|
15.29 | 2.37B | 630.20M | 37.73M | -17.44M | 0.20 |
|
HLN
Haleon Plc Adr
|
11.07 | 50.98B | 14.35B | 1.85B | 0 | 0.4023 |
|
ZTS
Zoetis Inc
|
169.78 | 74.41B | 9.29B | 2.52B | 2.28B | 5.57 |
|
RDHL
Redhill Biopharma Ltd Adr
|
1.935 | 4.03M | 35.75M | 11.57M | -26.25M | -3.8069 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.93 | 46.23B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.55 | 20.10B | 16.54B | -1.64B | 749.00M | -1.45 |
Hutchmed China Limited Adr Stock (HCM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-13 | Herabstufung | HSBC Securities | Buy → Hold |
| 2023-11-24 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2022-05-04 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2021-09-22 | Herabstufung | Goldman | Buy → Neutral |
| 2021-08-03 | Eingeleitet | Jefferies | Buy |
| 2020-10-02 | Eingeleitet | Deutsche Bank | Buy |
| 2020-03-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-02-20 | Eingeleitet | Goldman | Buy |
| 2019-11-19 | Eingeleitet | CLSA | Buy |
| 2019-10-23 | Bestätigt | BofA/Merrill | Buy |
| 2019-07-05 | Eingeleitet | Macquarie | Outperform |
Alle ansehen
Hutchmed China Limited Adr Aktie (HCM) Neueste Nachrichten
Wall Street Analysts See a 68.3% Upside in HUTCHMED (HCM): Can the Stock Really Move This High? - sharewise
Market news - investments.halifax.co.uk
Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Renal Cell Carcinoma - Yahoo Finance
HUTCHMED and Innovent Jointly Announce NDA Acceptance in - GlobeNewswire
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma - GlobeNewswire Inc.
Northern Trust Corp Sells 10,700 Shares of HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World
Millennium Management LLC Sells 100,366 Shares of HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World
D. E. Shaw & Co. Inc. Trims Position in HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World
BNP Paribas Financial Markets Trims Stock Position in HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World
Jane Street Group LLC Grows Position in HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World
Barclays PLC Purchases 2,255 Shares of HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing - The Manila Times
UPDATEInternational companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 15, 2025 - The Globe and Mail
International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on May 15, 2025 - The Manila Times
International companies to host live webcasts at Deutsche - GlobeNewswire
HUTCHMED and AstraZeneca Announce that TAGRISSO® Plus Savolitinib Demonstrated 49% Objective Response Rate in Lung Cancer Patients with High Levels of MET Overexpression and/or Amplification in SAVANNAH Phase II Trial - Barchart.com
Marshall Wace LLP Acquires New Holdings in HUTCHMED (China) Limited (NASDAQ:HCM) - The AM Reporter
CN Reportedly Directs Pharmas, Hospitals to Study Feasibility of Substituting US Imported Products - AASTOCKS.com
RCSHutchmed China LtdHUTCHMEDData to be Presented at AACR 2025 - TradingView
HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China - Yahoo Finance
HUTCHMEDOncology portfolio growth expected to continue - Research Tree
HUTCHMED (China) Limited (NASDAQ:HCM) Shares Sold by Connor Clark & Lunn Investment Management Ltd. - Defense World
Richard Li Invited to Attend China Development Forum, Pictured with Li Qiang and Others - AASTOCKS.com
Intended Retirement of Independent Non-executive Directors and changes of composition of board committees - GlobeNewswire
HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025 - GlobeNewswire
Innovent and HUTCHMED Jointly Announce that the FRUSICA-2 Phase 2/3 Study of Sintilimab and Fruquintinib Combination Has Met Its Primary Endpoint in Advanced Renal Cell Carcinoma in China - The Manila Times
HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 - GlobeNewswire
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 8th and 9th, 2023 - AsiaOne
HUTCHMED (HCM) Upgraded to Buy: Here's Why - Yahoo Finance
Wall Street Analysts Believe HUTCHMED (HCM) Could Rally 72.83%: Here's is How to Trade - Yahoo Finance
CN NMPA Guides Pharmas, Research Institutes to Enlarge R&D of Innovative Drugs, High-Quality Generic Drugs - AASTOCKS.com
ABC Arbitrage SA Buys New Holdings in HUTCHMED (China) Limited (NASDAQ:HCM) - MarketBeat
Sea Limited Sponsored ADR (SE) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance
Crossmark Global Holdings Inc. Increases Stock Position in HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World
CN Healthcare Fund Breaks even w/ Slim Surplus in 2024 - AASTOCKS.com
HUTCHMED Announces NMPA Full Approval for - GlobeNewswire
UBS Trims HUTCHMED (00013.HK)TP to $38.7 w/ Rating Buy - AASTOCKS.com
Private equity firms are HUTCHMED (China) Limited's (LON:HCM) biggest owners and were rewarded after market cap rose by UK£120m last week - Yahoo Finance
HSBC Global Research Prefers BeiGene/ SINO BIOPHARM/ HYGEIA HEALTH Given Higher Visibility in CN Pharma & Medical Device Subsectors - AASTOCKS.com
Hutchmed announces progress, hits milestone with lung cancer treatment - ShareCast
Savolitinib Plus Osimertinib Receives Priority Review in China for Pretreated EGFR+ NSCLC With a MET Amplification - OncLive
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy - The Manila Times
HUTCHMED Announces NDA Acceptance in China with Priority - GlobeNewswire
Jane Street Group LLC Raises Stock Holdings in HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World
HUTCHMED (China) Limited (NASDAQ:HCM) Shares Purchased by State Street Corp - Defense World
HCMHUTCHMED (China) Limited American Depositary Shares Latest Stock News & Market Updates - StockTitan
HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy - The Manila Times
HUTCHMED Announces Breakthrough Therapy Designation in - GlobeNewswire
Finanzdaten der Hutchmed China Limited Adr-Aktie (HCM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
0.95%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):